维普中文期刊产品整合服务
16篇 您的检索式:作者名="Gareth Morgan"
    题名 作者 年代 出处 被引量
1Thirteen 'must ask' questions a- bout e-learning products and services显示文摘MORGAN GARETH 2001The Learning Organization2001,8,5:1
2The case for qualitative research显示文摘Gareth Morgan and Linda Smircich 1980The Academy of Management Review1980,5,4:1
311β-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects显示文摘Laura L. Gathercole Gareth G. Lavery Stuart A. Morgan Mark S. Cooper Alexandra J. Sinclair Jeremy W. Tomlinson Paul M. Stewart 2013Endocrine Reviews2013,,4:1
4Differences in Matrix Metalloproteinase-1 and Matrix Metalloproteinase-12 Transcript Levels Among Carotid Atherosclerotic Plaques With Different Histopathological Characteristics显示文摘Angharad R. Morgan Kittipan Rerkasem Patrick J. Gallagher Baiping Zhang Gareth E. Morris Philip C. Calder Robert F. Grimble Per Eriksson William L. McPheat Clifford P. Shearman Shu Ye 2004Stroke: Journal of the American Heart Association2004,,6:1
5Systemic Blood Pressure After Stent Management for Arch Coarctation Implications for Clinical Care显示文摘Gareth J. Morgan Kyong Jin Lee Rajiv Chaturvedi Timothy J. Bradley Luc Mertens Lee Benson 2013JACC: Cardiovascular Interventions2013,,:1
6The risks and benefits of prophylactic aspirin in vascular disease and cancer显示文摘Peter C Elwood Mohammed Mustafa Maribel Almonte Gareth Morgan 2012Clin. Invest2012,,12:1
7Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress显示文摘Lei Zhang Jacqueline J.L. Fok Fabio Mirabella Lauren I. Aronson Rosemary A. Fryer Paul Workman Gareth J. Morgan Faith E. Davies 2013Cancer Letters2013,,:1
8First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial显示文摘Gareth J Morgan Faith E Davies Walter M Gregory Kim Cocks Sue E Bell Alex J Szubert Nuria Navarro-Coy Mark T Drayson Roger G Owen Sylvia Feyler A John Ashcroft Fiona Ross Jennifer Byrne Huw Roddie Claudius Rudin Gordon Cook Graham H Jackson J Anthony Chil 2010The Lancet . 2010 (9757)2010,,:1
9Farmers’ Attitudes, Objectives, Behaviors, and Personality Traits: The Edinburgh Study of Decision Making on Farms显示文摘Joyce Willock Ian J. Deary Murray M. McGregor Alister Sutherland Gareth Edwards-Jones Oliver Morgan Barry Dent Robert Grieve Gavin Gibson Elizabeth Austin 1999Journal of Vocational Behavior1999,,1:1
10The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence显示文摘Hai Rim Shin Joon Youn Kim Taik Koo Yun Gareth Morgan Harri Vainio 2000Cancer Causes and Control2000,,6:1
11Thoracic aorta at multi-detector row CT: motion artifact with various reconstruction windows显示文摘Gareth J Morgan H Patrick E 2003Radiology2003,228,:1
12Precise Subpixel Disparity Measurement from Very Narrow Baseline Stereo 显示文摘Gareth Llewellyn Keith Morgan Jian Guo Liu Hongshi Yan 2010IEEE TRANSACTIONS ON GEOSCIENCE AND REMOTE SENSING2010,48,9:1
13Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial显示文摘Gareth J Morgan J Anthony Child Walter M Gregory Alex J Szubert Kim Cocks Sue E Bell Nuria Navarro-Coy Mark T Drayson Roger G Owen Sylvia Feyler A John Ashcroft Fiona M Ross Jennifer Byrne Huw Roddie Claudius Rudin Gordon Cook Graham H Jackson Ping Wu Fai 2011Lancet Oncology2011,,8:1
14Medium-term mortality after hip fractures and COVID-19:A prospective multicentre UK study显示文摘Purpose:The COVID-19 pandemic has caused 1.4 million deaths globally and is associated with a 3-4 times increase in 30-day mortality after a fragility hip fracture with concurrent COVID-19 infection.Typically,death from COVID-19 infection occurs between 15 and 22 days after the onset of symptoms,but this period can extend up to 8 weeks.This study aimed to assess the impact of concurrent COVID-19 infection on 120-day mortality after a fragility hip fracture.Methods:A multi-centre prospective study across 10 hospitals treating 8%of the annual burden of hip fractures in England between 1st March and 30th April,2020 was performed.Patients whose surgical treatment was payable through the National Health Service Best Practice Tariff mechanism for'fragility hip fractures'were included in the study.Patients'120-day mortality was assessed relative to their perioperative COVID-19 status.Statistical analysis was performed using SPSS version 27.Results:A total of 746 patients were included in this study,of which 87(11.7%)were COVID-19 positive.Mortality rates at 30-and 120-day were significantly higher for COVID-19 positive patients relative to COVID-19 negative patients(p<0.001).However,mortality rates between 31 and 120-day were not significantly different(p=0.107),16.1%and 9.4%respectively for COVID-19 positive and negative patients,odds ratio 1.855(95%CI 0.865-3.978).Conclusion:Hip fracture patients with concurrent COVID-19 infection,provided that they are alive at day-31 after injury,have no significant difference in 120-day mortality.Despite the growing awareness and concern of 'long-COVID'and its widespread prevalence,this does not appear to increase mediumterm mortality rates after a hip fracture.Gareth Chan Ashish Narang Arash Aframian Zaid Ali Joseph Bridgeman Alastair Carr Laura Chapman Henry Goodier Catrin Morgan Chang Park Sarah Sexton Kapil Sugand Thomas Walton Michael Wilson Ajay Belgaumkar Kieran Gallagher Koushik Ghosh Charles Gibbons Joshua Jacob Andrew Keightley Zuhair Nawaz Khaled Sarraf Christopher Wakeling William Kieffer Benedict Rogers 2022Chinese Journal of Traumatology2022,25,3:0
15For teachers:Stories behind Words显示文摘活动一:阅读故事 适合年级:小学五、六年级 时间:20分钟 材料准备:为每位学生复印阅读材料 活动过程:1.教师提问:What’s your Chinese name?What does it mean?学生可以用英语或汉语回答。Gareth Morgan 张鲁静 2008中小学外语教学(下半月)2008,,12:0
16Mid-Term Preliminary Results for Safety and Patency of the Occlutech Atrial Flow Regulator in an Animal Model显示文摘Objective:The Atrial Flow Regulator(AFR)is a double disc device made of self-expanding Nitinol wire mesh,structured around a central lumen.Once deployed via the transfemoral route,the device stents the atrial septum leaving a preselected fixed diameter atrial communication.We sought to evaluate the mid-term performance of the AFR by implanting the device in 5 healthy porcine hearts to assess safety and patency of the device fenestration over a period of 150 days.Method:Five AFR devices were implanted in 5 female Yucatan adult minipigs.The animals were survived to 150 days with periodic assessments at days+3,+30,+60,+90,+120,and+150.These assessments consisted of transesophageal echocardiography and fluoroscopic evaluation.The animals were sacrificed at day+150.Histological and pathological assessments were carried out to characterize neointimal tissue growth,inflammation,thrombus formation,endothelial coverage,endothelial maturity,and the presence of any luminal thrombus.Result:There were no unscheduled deaths.Patency was maintained in all 5 animals across the 150-day study.There was no statistically significant difference in the lumen diameter over the study duration.Neointimal growth was mild to moderate in all specimens and occurred mostly on the surfaces of the device in direct contact with the atrial septum.There was no evidence of any significant inflammatory response on routine blood work or by imaging or histological assessment.Scanning electron microscope(SEM)examination showed nearly complete surface coverage with endothelial tissue.The animals were in a healthy condition for the duration of the study with no attributable pathology and no adverse effects noted on distant organs in any of the 5 animals.Conclusion:As a continuation of our earlier work,this 150-day midterm animal study provides important safety and feasibility information.Our preliminary results show that the AFR is both safe and effective in maintaining a sustainable atrial level communication for the duration of the study.Kamel Shibbani Daniel McLennan Dunbar Ivy Gareth Morgan 2022Congenital Heart Disease2022,17,3:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费